Previous Close | 0.3583 |
Open | 0.3762 |
Bid | 0.0000 x 900 |
Ask | 0.0000 x 3200 |
Day's Range | 0.3570 - 0.3851 |
52 Week Range | 0.3500 - 5.2000 |
Volume | |
Avg. Volume | 334,846 |
Market Cap | 11.314M |
Beta (5Y Monthly) | 1.95 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -3.0550 |
Earnings Date | Mar 02, 2022 - Mar 07, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | Aug 20, 2015 |
1y Target Est | 11.67 |
SOUTH SAN FRANCISCO, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the first quarter ended March 31, 2022. “In the first quarter, we regained the rights to CB 2782-PEG, a C3 degrader protease, for the potential treatment of dry age-related macular degeneration (“AMD”) and now have full rights to two wholly-owned, potential best-in-class complement candidates that may provide compelling opportunities in o
We can readily understand why investors are attracted to unprofitable companies. For example, although...
SOUTH SAN FRANCISCO, Calif., March 31, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the fourth quarter and year ended December 31, 2021 and provided a corporate update. “In late 2021 we announced a strategic change in corporate strategy, pivoting from hemophilia to a highly promising complement therapeutics and protease medicines platform,” said Nassim Usman, Ph.D., president and chief executive officer of Catalyst. “T